Shanghai Zhongshan Hospital: Cholangiocarcinoma trials

The registry lists 16 Cholangiocarcinoma studies with Shanghai Zhongshan Hospital as lead sponsor. 5 are open to participants now and 0 have results posted.

Phase 1 1Phase 2 11Phase 3 2No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Safety and Efficacy of CD160-Enhanced Autologous Antigen-Specific T-Cells (BTC-Ag-T) in Advanced Biliary Tract CancerRecruitingNCT07614061Phase 1
• Chidamide Combined With Chemotherapy and Immunotherapy as First-line Treatment for Advanced Intrahepatic CholangiocarcinomaRecruitingNCT07570849Phase 2
• Anti-PD-1/PD-L1 Antibodies Plus Gemcitabine and Cisplatin for Advanced CCARecruitingNCT07291063
• A Randomized Trial of Surgical Decision-Making Guided by TDTP-RECISTNot yet recruitingNCT07208526Not applicable
• Second-line Regimen Combined With Radiotherapy Versus Without Radiotherapy in Patients With Locally Advanced/Oligometastatic ICC After Failure of First-line Treatment：an Open-label, Randomized, Controlled Phase II Clinical StudyNot yet recruitingNCT06946849Phase 2
• Comparing the TDTP-RECIST With RECIST 1.1 and Other Volumetric Evaluation Methods for Assessing the Therapeutic Efficacy of Irregular Malignant TumorsCompletedNCT07319767
• Anti-PD1 Antibody Toripalimab Combined With Gemox as First-line Therapy in Late-stage Intrahepatic CholangiocarcinomaStatus unknownNCT04961788Phase 2
• Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence FactorsActive, not recruitingNCT04669496Phase 2/3
• PD-L1 Antibody Combined With CTLA-4 Antibody for Patients With Advanced Intrahepatic Cholangiocarcinoma Who Progressed After Standard TreatmentActive, not recruitingNCT04634058Phase 2
• Cisplatin and Gemcitabine Chemotherapy and Lenvatinib for Patients With Unresectable Intrahepatic CholangiocarcinomaStatus unknownNCT04527679Phase 2
• PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence FactorsStatus unknownNCT04506281Phase 2
• Two-cohort Study of Toripalimab(PD1)+Lenvatnib, or Gemox+Lenvatinib in Advanced Intrahepatic CholangiocarcinomaCompletedNCT04361331Phase 2
• PD-1 Antibody (SHR-1210) Plus Capecitabine in Patients with Intrahepatic Cholangiocarcinoma After SurgeryActive, not recruitingNCT04295317Phase 2
• Nab-Paclitaxel Combined With Gemcitabine Adjuvant Chemotherapy After Radical Resection of Intrahepatic CholangiocarcinomaStatus unknownNCT04077983Phase 2
• Combined Therapy Using Oxaliplatin and Gemcitabine Chemotherapy, Lenvatinib and PD1 Antibody (JS001) for Patients With Advanced and Unresectable Intrahepatic CholangiocarcinomaStatus unknownNCT03951597Phase 2
• Oxaliplatin+Gemcitabine vs Capecitabine as Adjuvant Therapy for Intrahepatic CholangiocarcinomaStatus unknownNCT02548195Phase 3